<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tectonic Therapeutic, Inc. — News on 6ix</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc</link>
<description>Latest news and press releases for Tectonic Therapeutic, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tectonic-therapeutic-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c8a178dffbe2df11bf3b.webp</url>
<title>Tectonic Therapeutic, Inc.</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc</link>
</image>
<item>
<title>Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-appoints-jessica-chutter-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-appoints-jessica-chutter-to-board-of-directors</guid>
<pubDate>Thu, 23 Apr 2026 20:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed Jessica Chutter to its Board of Directors, effective June 8, 2026. Ms. Chutter brings more than four decades of experience in global healthcare investment banking, with dee</description>
</item>
<item>
<title>Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Announced positive topline results from TX45 Phase 1b acute hemodynamic clinical trial in patients with Group 2 Pulmonary Hypertension in Heart Failure with</description>
</item>
<item>
<title>Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-appoints-francois-nader-md-as-chair-and-independent-director-of-the-board</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-appoints-francois-nader-md-as-chair-and-independent-director-of-the-board</guid>
<pubDate>Mon, 23 Feb 2026 21:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. D</description>
</item>
<item>
<title>Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-host-virtual-kol-210100757</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-host-virtual-kol-210100757</guid>
<pubDate>Wed, 11 Feb 2026 21:01:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), announced that it will host a virtual key opinion leader (KOL) event and TX2100 discussion on Tuesday, February 24, 2026 from 11:00 a.m. to 12:30 p.m. ET. The event will feature Hanny Al-Samkari, MD (Massac</description>
</item>
<item>
<title>Tectonic Therapeutic to Participate in December Investor Conferences</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-participate-december-investor-130000985</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-participate-december-investor-130000985</guid>
<pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in December 2025. Piper Sandler 37th Annual Healthcare Conference Date:Time:Location:Format:Present</description>
</item>
<item>
<title>Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-third-quarter-210100963</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-third-quarter-210100963</guid>
<pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
<description>Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH-HFrEF”)Expect to initiate TX2100 Phase 1 clinical trial in healthy volunteers in Q1’2026 as a potential treatment for Hereditary Hemorrhagic Telangiectasia (“HHT”)TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety an</description>
</item>
<item>
<title>Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-positive-topline-200100092</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-positive-topline-200100092</guid>
<pubDate>Wed, 29 Oct 2025 20:01:00 GMT</pubDate>
<description>TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”)TX45 was well tolerated in patients with PH‑HFrEF with no serious or severe adverse events, no clinically significant changes in blood pressure and no immune related reactionsResults support potential expansion of TX45’s addressable Group 2 PH patient population to PH‑HFrEFCompany to host webcast today, October 29th at 4:30</description>
</item>
<item>
<title>Tectonic Therapeutic to Participate in September Investor Conferences</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-participate-september-investor-130000852</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-participate-september-investor-130000852</guid>
<pubDate>Thu, 28 Aug 2025 13:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston,</description>
</item>
<item>
<title>Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-second-quarter-200100834</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-second-quarter-200100834</guid>
<pubDate>Thu, 07 Aug 2025 20:01:00 GMT</pubDate>
<description>TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45’s safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease (“PH-ILD”, Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Group 2</description>
</item>
<item>
<title>Tectonic Therapeutic Joins Russell 3000® Index</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-joins-russell-3000-120000042</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-joins-russell-3000-120000042</guid>
<pubDate>Mon, 30 Jun 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic’s addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the ope</description>
</item>
<item>
<title>Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-presents-complete-results-144000096</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-presents-complete-results-144000096</guid>
<pubDate>Sat, 17 May 2025 14:40:00 GMT</pubDate>
<description>Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”)In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions (“LVEF”), including LVEF≥50% and LVEF 41-49% WA</description>
</item>
<item>
<title>Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-first-quarter-200100383</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-first-quarter-200100383</guid>
<pubDate>Thu, 08 May 2025 20:01:00 GMT</pubDate>
<description>Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results e</description>
</item>
<item>
<title>Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-present-may-15th-120000833</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-present-may-15th-120000833</guid>
<pubDate>Wed, 07 May 2025 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank o</description>
</item>
<item>
<title>Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-present-phase-1b-120000636</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-present-phase-1b-120000636</guid>
<pubDate>Tue, 15 Apr 2025 12:00:00 GMT</pubDate>
<description>Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that i</description>
</item>
<item>
<title>Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-fourth-quarter-200100340</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-fourth-quarter-200100340</guid>
<pubDate>Thu, 20 Mar 2025 20:01:00 GMT</pubDate>
<description>TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”)Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction (“H</description>
</item>
<item>
<title>Tectonic Therapeutic to Participate in March Investor Conferences</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-participate-march-investor-130000789</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-participate-march-investor-130000789</guid>
<pubDate>Thu, 20 Feb 2025 13:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025. TD Cowen 45th Annual Health Care Conference Date:March 5, 2025Time:9:50 AM ESTLocati</description>
</item>
<item>
<title>Tectonic Announces $185 Million Private Placement</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-announces-dollar185-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-announces-dollar185-million-private-placement</guid>
<pubDate>Mon, 03 Feb 2025 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced that it has entered into a</description>
</item>
<item>
<title>Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-positive-interim-data-from-phase-1b-trial-for-tx45-in-patients-with-group-2-pulmonary-hypertension-in-hfpef</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-announces-positive-interim-data-from-phase-1b-trial-for-tx45-in-patients-with-group-2-pulmonary-hypertension-in-hfpef</guid>
<pubDate>Thu, 30 Jan 2025 05:00:00 GMT</pubDate>
<description>TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved</description>
</item>
<item>
<title>Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-to-host-kol-event-on-the-unmet-need-in-group-2-ph-hfpef-and-tx45-as-a-potential-treatment-on-thursday-december-12-2024</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-to-host-kol-event-on-the-unmet-need-in-group-2-ph-hfpef-and-tx45-as-a-potential-treatment-on-thursday-december-12-2024</guid>
<pubDate>Tue, 03 Dec 2024 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on</description>
</item>
<item>
<title>Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference</title>
<link>https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-to-present-on-december-3rd-2024-at-the-piper-sandler-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/tectonic-therapeutic-inc/news/tectonic-therapeutic-to-present-on-december-3rd-2024-at-the-piper-sandler-healthcare-conference</guid>
<pubDate>Tue, 26 Nov 2024 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on</description>
</item>
</channel>
</rss>